Parkinson's disease (PD) is a progressive neurological disorder affecting an estimated 1 to 1.5 million people in the United States and 4 to 7 million people worldwide.
The goal of PDTrialTracker.info is to provide Parkinson's patients, families, researchers, health care providers, and other interested members of the PD community with analysis of ongoing PD clinical trials and observational studies throughout the world in order to:
Clinical Trial Data Source
Clinical trial and study data on PDTrialTracker.info are obtained from the ClinicalTrials.gov database, a web-based resource that provides information to the public, free of charge, on publicly and privately supported clinical studies on a wide range of diseases and conditions. Launched in February 2000, ClinicalTrials.gov is maintained by the National Library of Medicine at the National Institutes of Health (NIH). See ClinicalTrials.gov overview.
Clinical trial data available on ClinicalTrials.gov is submitted directly by each study's sponsor or principal investigator. To date, over 2000 Parkinson's disease trials/studies from around the world have been listed on ClinicalTrials.gov, with over 600 of these currently active.
PDTrialTracker monitors and analyzes Parkinson's disease clinical trials and observational studies that are in-progress, that is, i) currently recruiting, ii) active, but not yet recruiting, iii) enrolling by invitation or iv) active, not recruiting. The analysis is presented in tabular and graphical formats to provide greater insight into the type and focus of trials underway.
High-level charts of the trial pipeline provide overall views of the number, types and locations of trials being conducted. You can drill-down into specific trials of interest through pre-set trial filters, such as trial type (interventional, observational), trial phase, recruiting status, and therapy focus. Direct links to interactive maps on ClinicalTrials.gov allow you to easily view filtered trial sets by country and state and to zoom in on individual trial details such as study methodology, inclusion/exclusion criteria, and study contact and location information.
These types of filtered data views can yield insights and suggest action plans to help streamline the trial process.
Insights developed through analysis of the PD clinical trial pipeline can foster further collaboration between patients and researchers. Greater awareness of ongoing research can enable patient advocates to work more closely with researchers on study design, funding, and recruitment efforts, thereby helping to accelerate the path to a cure.
See recruiting trials page to view recruiting trial information via interactive map tools.
See collaboration page to learn about opportunities for patient/researcher collaboration.
* 30 trials are combined Phase 1/2 or combined Phase 2/3
Active PD Clinical Trials Worldwide
Note: Interventional studies in Phase 1, 2 or 3 evaluate the safety and efficacy of a medication, device, or procedure for the treatment of a medical condition. Phase 4 studies further evaluate a drug or device that has already been FDA-approved. Studies with no phase specified can include evaluations of interventions such as exercise, physical therapy, speech therapy, dietary supplements and more.
Note: Active PD trials include those:
i) currently recruiting, ii) not yet recruiting, iii) enrolling by invitation and
iv) in-progress, not recruiting.
Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.